SCHEMBL6317243

SCHEMBL6317243

COCCCNC(=O)c1c(-c2ccc(C)s2)noc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
RECQL P46063 1/20 0.41
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GABRA5 P31644 1/20 0.39
KDR P35968 1/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 1/20 0.39
ATM Q13315 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317440 0.89 RXFP1 (0.41) GAAALDH1A1CA1CA2CA4
SCHEMBL6324126 0.89 CA1 (0.54) GAAALDH1A1CA1CA2CA4
SCHEMBL6317644 0.89 GAA (0.44) GAAALDH1A1CA1CA2CA4
SCHEMBL6321826 0.88 GAA (0.43) GAAALDH1A1CA1CA2CA4
SCHEMBL6319057 0.87 ALOX15 (0.43) GAAALDH1A1CA1CA2CA4
SCHEMBL6322769 0.87 ALOX15 (0.43) GAAALDH1A1CA1CA2CA4
SCHEMBL6324330 0.87 ALOX15 (0.43) GAAALDH1A1CA1CA2CA4
SCHEMBL6324224 0.86 CA1 (0.44) GAAALDH1A1CA1CA2CA4
SCHEMBL6315066 0.84 L3MBTL1 (0.59) GAAALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6316101 0.83 CA1 (0.42) GAAALDH1A1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GAA 789/4885ALDH1A1 4444/4885CA1 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.